Autoantibodies in cancer

Prognostic biomarkers and immune activation

Kerstin Järås, Karen Anderson

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The development of proteomic technologies that display a wide variety of antigenic structures has led to the identification of autoantibodies to cancer-derived tumor antigens. These autoantibodies have been detected in sera from patients with multiple cancer types, and are being evaluated as biomarkers for early cancer detection. It is not known whether these antibodies also contribute to active immune surveillance or even tumorigenicity of developing tumors. Here, we review which tumor antigen-specific antibodies are prognostic biomarkers of cancer outcome, and emerging proteomic methods for the isolation and cloning of these antibodies for potential molecular diagnostics and therapeutics.

Original languageEnglish (US)
Pages (from-to)577-589
Number of pages13
JournalExpert Review of Proteomics
Volume8
Issue number5
DOIs
StatePublished - Oct 2011

Fingerprint

Tumor Biomarkers
Autoantibodies
Chemical activation
Neoplasm Antigens
Proteomics
Antibodies
Neoplasms
Molecular Pathology
Cloning
Biomarkers
Early Detection of Cancer
Organism Cloning
Tumors
Technology
Serum
Therapeutics

Keywords

  • autoantibodies
  • cancer
  • clinical outcome
  • function
  • human monoclonal antibodies
  • prognosis
  • prognostic
  • recurrence
  • survival
  • therapeutic antibodies
  • tumor antigens

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry

Cite this

Autoantibodies in cancer : Prognostic biomarkers and immune activation. / Järås, Kerstin; Anderson, Karen.

In: Expert Review of Proteomics, Vol. 8, No. 5, 10.2011, p. 577-589.

Research output: Contribution to journalArticle

@article{6f19e32443154e07a4664ff2f4af6a08,
title = "Autoantibodies in cancer: Prognostic biomarkers and immune activation",
abstract = "The development of proteomic technologies that display a wide variety of antigenic structures has led to the identification of autoantibodies to cancer-derived tumor antigens. These autoantibodies have been detected in sera from patients with multiple cancer types, and are being evaluated as biomarkers for early cancer detection. It is not known whether these antibodies also contribute to active immune surveillance or even tumorigenicity of developing tumors. Here, we review which tumor antigen-specific antibodies are prognostic biomarkers of cancer outcome, and emerging proteomic methods for the isolation and cloning of these antibodies for potential molecular diagnostics and therapeutics.",
keywords = "autoantibodies, cancer, clinical outcome, function, human monoclonal antibodies, prognosis, prognostic, recurrence, survival, therapeutic antibodies, tumor antigens",
author = "Kerstin J{\"a}r{\aa}s and Karen Anderson",
year = "2011",
month = "10",
doi = "10.1586/epr.11.48",
language = "English (US)",
volume = "8",
pages = "577--589",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Autoantibodies in cancer

T2 - Prognostic biomarkers and immune activation

AU - Järås, Kerstin

AU - Anderson, Karen

PY - 2011/10

Y1 - 2011/10

N2 - The development of proteomic technologies that display a wide variety of antigenic structures has led to the identification of autoantibodies to cancer-derived tumor antigens. These autoantibodies have been detected in sera from patients with multiple cancer types, and are being evaluated as biomarkers for early cancer detection. It is not known whether these antibodies also contribute to active immune surveillance or even tumorigenicity of developing tumors. Here, we review which tumor antigen-specific antibodies are prognostic biomarkers of cancer outcome, and emerging proteomic methods for the isolation and cloning of these antibodies for potential molecular diagnostics and therapeutics.

AB - The development of proteomic technologies that display a wide variety of antigenic structures has led to the identification of autoantibodies to cancer-derived tumor antigens. These autoantibodies have been detected in sera from patients with multiple cancer types, and are being evaluated as biomarkers for early cancer detection. It is not known whether these antibodies also contribute to active immune surveillance or even tumorigenicity of developing tumors. Here, we review which tumor antigen-specific antibodies are prognostic biomarkers of cancer outcome, and emerging proteomic methods for the isolation and cloning of these antibodies for potential molecular diagnostics and therapeutics.

KW - autoantibodies

KW - cancer

KW - clinical outcome

KW - function

KW - human monoclonal antibodies

KW - prognosis

KW - prognostic

KW - recurrence

KW - survival

KW - therapeutic antibodies

KW - tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=80054732684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054732684&partnerID=8YFLogxK

U2 - 10.1586/epr.11.48

DO - 10.1586/epr.11.48

M3 - Article

VL - 8

SP - 577

EP - 589

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 5

ER -